AbbVie Inc (ABBV) : Financial Engines Advisors L.l.c. reduced its stake in AbbVie Inc by 25.31% during the most recent quarter end. The investment management company now holds a total of 169,634 shares of AbbVie Inc which is valued at $11,397,708 after selling 57,472 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.AbbVie Inc makes up approximately 9.13% of Financial Engines Advisors L.l.c.’s portfolio.
Other Hedge Funds, Including , Sigma Planning Corp reduced its stake in ABBV by selling 33,339 shares or 44.5% in the most recent quarter. The Hedge Fund company now holds 41,584 shares of ABBV which is valued at $2,653,475. AbbVie Inc makes up approx 0.34% of Sigma Planning Corp’s portfolio.Pineno Levin Ford Asset Management reduced its stake in ABBV by selling 50 shares or 0.11% in the most recent quarter. The Hedge Fund company now holds 46,460 shares of ABBV which is valued at $2,964,613. AbbVie Inc makes up approx 1.49% of Pineno Levin Ford Asset Management’s portfolio.North American Management Corp reduced its stake in ABBV by selling 350 shares or 2.87% in the most recent quarter. The Hedge Fund company now holds 11,847 shares of ABBV which is valued at $751,218. AbbVie Inc makes up approx 0.12% of North American Management Corp’s portfolio.Vigilant Capital Management reduced its stake in ABBV by selling 3,305 shares or 2.31% in the most recent quarter. The Hedge Fund company now holds 139,875 shares of ABBV which is valued at $8,869,474. AbbVie Inc makes up approx 1.65% of Vigilant Capital Management’s portfolio.
AbbVie Inc opened for trading at $66.57 and hit $67.18 on the upside on Friday, eventually ending the session at $67.1, with a gain of 0.49% or 0.33 points. The heightened volatility saw the trading volume jump to 67,09,360 shares. Company has a market cap of $109,275 M.
On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.